Phylicia Stathi
YOU?
Author Swipe
View article: Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma
Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma Open
Next Generation Sequencing-based subtyping and interim- and end of treatment positron emission tomography (i/eot-PET) monitoring have high potential for upfront and on-treatment risk assessment of diffuse large B-cell lymphoma patients. We…
View article: Supplementary Tables from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell
Supplementary Tables from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell Open
Supplementary Tables
View article: Data from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell
Data from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell Open
Large B-cell lymphoma of immune privileged sites (LBCL-IP) arise in immune sanctuaries including the testis and central nervous system. After initially reaching complete response, relapses occur in almost 50% of patients, typically at othe…
View article: Supplementary Data from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell
Supplementary Data from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell Open
Supplementary Data
View article: Supplementary Data from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell
Supplementary Data from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell Open
Supplementary Data
View article: Supplementary Tables from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell
Supplementary Tables from Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell Open
Supplementary Tables
View article: The Impact of Genetic Subtypes of Diffuse Large B-Cell Lymphoma for Outcome Prediction and Interpretation of FDG-PET treatment Response Monitoring
The Impact of Genetic Subtypes of Diffuse Large B-Cell Lymphoma for Outcome Prediction and Interpretation of FDG-PET treatment Response Monitoring Open
Next-generation sequencing (NGS)-based genetic subtyping and interim- and end-of-treatment 18fluorodeoxyglucose-positron emission tomography (i/eot-PET) have high potential for upfront and on-treatment risk assessment to guide personalized…
View article: Multi-scale spatial modeling of immune cell distributions enables survival prediction in primary central nervous system lymphoma
Multi-scale spatial modeling of immune cell distributions enables survival prediction in primary central nervous system lymphoma Open
To understand the clinical significance of the tumor microenvironment (TME), it is essential to study the interactions between malignant and non-malignant cells in clinical specimens. Here, we established a computational framework for a mu…
View article: Data from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell
Data from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell Open
Large B-cell lymphoma of immune-privileged sites (LBCL-IP) arise in immune sanctuaries including the testis and central nervous system (CNS). After initially reaching complete response, relapses occur in almost 50% of patients, typically a…
View article: Supplementary Tables from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell
Supplementary Tables from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell Open
Supplementary Tables
View article: Supplementary Data from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell
Supplementary Data from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell Open
Supplementary Data
View article: Supplementary Data from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell
Supplementary Data from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell Open
Supplementary Data
View article: Supplementary Tables from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell
Supplementary Tables from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell Open
Supplementary Tables
View article: Supplementary Data from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell
Supplementary Data from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell Open
Supplementary Data
View article: Supplementary Data from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell
Supplementary Data from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell Open
Supplementary Data
View article: Supplementary Tables from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell
Supplementary Tables from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell Open
Supplementary Tables
View article: Data from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell
Data from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell Open
Large B-cell lymphoma of immune-privileged sites (LBCL-IP) arise in immune sanctuaries including the testis and central nervous system (CNS). After initially reaching complete response, relapses occur in almost 50% of patients, typically a…
View article: Data from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell
Data from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell Open
Large B-cell lymphoma of immune-privileged sites (LBCL-IP) arise in immune sanctuaries including the testis and central nervous system (CNS). After initially reaching complete response, relapses occur in almost 50% of patients, typically a…
View article: Supplementary Tables from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell
Supplementary Tables from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell Open
Supplementary Tables
View article: Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment
Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment Open
International audience
View article: Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell
Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell Open
Large B-cell lymphoma of immune-privileged sites (LBCL-IP) arise in immune sanctuaries including the testis and central nervous system (CNS). After initially reaching complete response, relapses occur in almost 50% of patients, typically a…
View article: Multi-scale spatial modeling of immune cell distributions enables survival prediction in primary central nervous system lymphoma
Multi-scale spatial modeling of immune cell distributions enables survival prediction in primary central nervous system lymphoma Open
To understand the clinical significance of the tumor microenvironment (TME), it is essential to study the interactions between malignant and non-malignant cells in clinical specimens. Here, we established a computational framework for a mu…
View article: Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV
Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV Open
Although the genomic and immune microenvironmental landscape of follicular lymphoma (FL) has been extensively investigated, little is known about the potential biological differences between stage I and stage III/IV disease. Using next-gen…
View article: Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment
Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment Open
Many refractory classical Hodgkin lymphoma (cHL) patients are uniquely susceptible to immune checkpoint PD-1 blockade (anti-PD-1). Because of these encouraging clinical results, anti-PD-1 is rapidly becoming an integral component of cHL tr…
View article: Extracellular vesicle miRNA predict FDG‐PET status in patients with classical Hodgkin Lymphoma
Extracellular vesicle miRNA predict FDG‐PET status in patients with classical Hodgkin Lymphoma Open
Minimally‐invasive tools to assess tumour presence and burden may improve clinical management. FDG‐PET (metabolic) imaging is the current gold standard for interim response assessment in patients with classical Hodgkin Lymphoma (cHL), but …
View article: Engineering large-scale chromosomal deletions by CRISPR-Cas9
Engineering large-scale chromosomal deletions by CRISPR-Cas9 Open
Large-scale chromosomal deletions are a prevalent and defining feature of cancer. A high degree of tumor-type and subtype specific recurrencies suggest a selective oncogenic advantage. However, due to their large size it has been difficult…
View article: Engineering large chromosomal deletions by CRISPR-Cas9
Engineering large chromosomal deletions by CRISPR-Cas9 Open
Arm-level chromosomal deletions are a prevalent and defining feature of cancer. A high degree of tumor-type and subtype specific recurrencies suggest a selective oncogenic advantage. However, due to their large size it has been difficult t…
View article: Chromosome 20 loss is characteristic of breast implant–associated anaplastic large cell lymphoma
Chromosome 20 loss is characteristic of breast implant–associated anaplastic large cell lymphoma Open
Breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) is a very rare type of T-cell lymphoma that is uniquely caused by a single environmental stimulus. Here, we present a comprehensive genetic analysis of a relatively large …